THERAPY DOSSIER · th-cc708674f51e

Vascular endothelial growth inhibitor (VEGI, also known as TL1A)

Biologic · Vascular endothelial growth inhibitor (VEGI/TL1A/TNFSF15); research biologic, no confident ChEMBL match

Evidence & regulatory context

Mechanism: Vascular endothelial growth inhibitor (VEGI/TL1A/TNFSF15); research biologic, no confident ChEMBL match
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26080076 ↗2015Reported benefit

VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-kB signaling pathway in experimental traumatic brain injury.

MouseTBIControlled cortical impactC57BL/6Male

Model: Experimental traumatic brain injury in mice producing a cortical contusion

Treatment reduced contusion tissue loss, inflammatory cell infiltration and microglial activation, increased tight junction proteins and Bcl-2, lowered TLR4, NF-kappaB and pro-inflammatory cytokines, and reduced Evans blue extravasation, indicating preserved blood-brain barrier integrity.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…